2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Alignment of objective markers of speech with listener based judgements and disease severity in Friedreich ataxia

A. Vogel, A. Tsanas, H. Reece, L. Corben, G. Tai, M. Delatycki (Melbourne, Australia)

Ataxia  ·  Les Muses, Level 3

1:45pm-3:15pm

Alleviation of Parkinson’s and Associated Depression using Silymarin in Rotenone induced Mice Model of Parkinson’s Disease

D. Khatri (Pune, India)

Neuropharmacology  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Alpha-synuclein promoter (SNCA-Rep1) polymorphism is associated with non-motor symptoms in early Parkinson’s disease

ASL. Ng, YJ. Tan, Y. Zhao, ZH. Lu, EYL. Ng, SYE. Ng, NSY. Chia, F. Setiawan, ZY. Xu, KY. Tay, WL. Au, EK. Tan, LCS. Tan (Singapore, Singapore)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Altered intrinsic power spectral density of the precuneus in patients with hyperkinetic functional movement disorders

R. Marapin, H. Horn, J. Gelauff, B. de Jong, Y. Dreissen, J. Koelman, R. Renken, J. Marsman, M. Tijssen (Groningen, Netherlands)

Functional (Psychogenic) Movement Disorders  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Amplification of α-synuclein aggregates in cerebrospinal fluid by rapid ultrasonication-based assay

K. Kakuda, K. Ikenaka, K. Araki, Y. Kajiyama, M. So, T. Ohmichi, Y. Nagai, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

An adult type Niemann-Pick disease type C family: Huntington’s disease-like expression

I. Toyoshima, F. Takeda, C. Wada (Yurihonjo, Japan)

Choreas (Non-Huntington’s Disease)  ·  Les Muses, Level 3

1:45pm-3:15pm

An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia

R. Ayyagari, D. Goldschmidt, F. Mu, S. Caroff, B. Carroll (Boston, MA, USA)

Quality of Life  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2

A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

An updated flow chart for the evaluation of chorea

R. Walker (Bronx, NY, USA)

Choreas (Non-Huntington’s Disease)  ·  Les Muses, Level 3

1:45pm-3:15pm

Analysis of Levodopa Content in Commercial Formulations of Mucuna pruriens Seeds Used in Integrative Treatment of Parkinson’s Disease

T. Denne (Kenmore, WA, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3